LOUISVILLE, Colo., Feb. 3 /PRNewswire/ -- Replidyne, Inc., a privately held biopharmaceutical company focused on the discovery and development of new anti-infective drugs, announced the election of Kirk K. Calhoun, retired partner of Ernst & Young LLP, as a member of its Board of Directors and Chairman of the Audit Committee.
Mr. Calhoun served for 27 years as a partner of Ernst & Young LLP until his retirement in June 2002. He has global experience in industries such as biotechnology, pharmaceutical and manufacturing. In particular, Mr. Calhoun has broad knowledge of audit committee functions and responsibilities and has counseled on complex accounting matters and strategic business issues.
"Kirk's extensive background in accounting issues and oversight makes him an outstanding addition to our board," said Kenneth Collins, President and Chief Executive Officer. "His experience and understanding of the biopharmaceutical industry will be a valuable asset to us as we move our products toward commercialization."
Mr. Calhoun is also a member of the Board of Directors of American Pharmaceutical Partners, Inc., Aspreva Pharmaceuticals Corporation, Myogen, Inc. and Adams Respiratory Therapeutics.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. Replidyne recently submitted an NDA to the FDA for its lead product, Orapem(TM), which is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other current development programs include higher dose/shorter course therapy, additional indications for adults, and a pediatric formulation of Orapem(TM). The Company's pipeline also includes a topical anti-bacterial product, REP8839, which has a novel mechanism of action for addressing the major challenge of methicillin-resistant Staphylococcus aureus (MRSA). Replidyne also has discovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. For additional information about Replidyne, Inc., please visit: www.replidyne.com.
Replidyne, Inc.CONTACT: Jill Clark of Replidyne, Inc., +1-303-996-5504
Web site: http://www.replidyne.com/
